Glatiramer Acetate

This tender pertains to the drug Glatiramer Acetate, specifically within the framework of program B29, which focuses on the treatment of patients with multiple sclerosis (MS). The procurement aims to secure a supply of Glatiramer Acetate for eligible patients. Glatiramer Acetate is a medication used to reduce the frequency of clinical relapses in individuals with relapsing-remitting multiple sclerosis. The tender likely involves detailed specifications for the pharmaceutical product, including dosage forms, packaging, and quality standards, as well as requirements for distribution and supply chain management. Healthcare providers or public health organizations are expected to issue this tender to ensure continuous access to this vital treatment for MS patients.

This is a supplies contract in the health and medical services sector. Located in Poland, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.